Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 2 , Pages 285-291, April 2008

Androgen deprivation therapy for precancerous lesions of the prostate

  • David Hull, MD (Staff Pathologist)
    • ,
  • David G. Bostwick, MD, MBA (CEO and Medical Director)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 804 967 9225; Fax: +1 804 545 1690.

Bostwick Laboratories, Inc., 4355 Innslake Drive, Glen Allen, VA 23060, USA

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1521-690X(08)00007-9

doi:10.1016/j.beem.2008.01.006

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 2 , Pages 285-291, April 2008

Article Tools

* Image Usage & Resolution